aHUS News

aHUS News is a digital resource designed to keep the atypical hemolytic uremic syndrome (aHUS) community updated with the latest news and insights. It also features personal stories and viewpoints from our patient and caregiver contributors. Every article on aHUS News is created by our dedicated team of writers and editors. From time to time, we invite external experts to share their knowledge through interviews and Q&A sessions. Our publishing team consists of science writers and editors, many of whom hold PhDs in life sciences, along with experienced journalists and columnists who are part of the AADC community. Together, they strive to ensure that all content on aHUS News is accurate, relevant, informative, and easy to understand for our readers.

National

English

Online/Digital

Outlet metrics

Domain Authority

Ranking

Global

#6054027

United States

#1983135

Articles

Switching from Soliris to Ultomiris safe, effective for aHUS: Study

3 days ago | ahusnews.com | Andrea Lobo

Switching from Soliris (eculizumab) to Ultomiris (ravulizumab) is a safe and effective treatment strategy for people with atypical hemolytic uremic syndrome (aHUS), according to a real-world study in Japan. The treatment switch was associated with stable levels of blood and kidney-related disease markers, preventing disease relapse or worsening and the need for additional treatment for most patients after one year, data showed.
Anti-CFH antibodies common cause of aHUS in India, study says

3 weeks ago | ahusnews.com | Andrea Lobo

More than half of people with atypical hemolytic uremic syndrome (aHUS) in India have self-reactive antibodies targeting complement factor H (CFH), a protein that regulates the activity of the complement system, according to a recent study. These patients generally had better outcomes, being less likely to develop end-stage kidney disease requiring dialysis than those without anti-CFH antibodies.
aHUS caused by lymphoma resolves after successful cancer treatment

1 month ago | ahusnews.com | Marisa Wexler

A woman in Italy developed atypical hemolytic uremic syndrome (aHUS) as a result of a blood cancer, which resolved after the cancer was brought into remission, a case study shows. The report, " Marginal zone lymphoma with anti-factor H IgM and atypical hemolytic uremic syndrome successfully treated with odronextamab ," was published in Haematologica.
Case highlights potential co-occurrence of pancreatitis and aHUS

1 month ago | ahusnews.com | Marisa Wexler

Inflammation of the pancreas, known as pancreatitis, can occur alongside the rare disease atypical hemolytic uremic syndrome (aHUS) - as a team of researchers from China highlighted in a new report outlining the case of a young woman found to have both conditions. The woman sought medical attention due to gastrointestinal issues, including abdominal pain and nausea.
Soliris helps manage aHUS in patient with neurological symptoms

1 month ago | ahusnews.com | Marisa Wexler

Soliris (eculizumab) helped control atypical hemolytic uremic syndrome (aHUS) in a patient whose symptoms included seizures and signs of neurological damage, according to a case report.
Soliris safe, effective as pediatric treatment for aHUS: Study

1 month ago | ahusnews.com | Margarida Maia

Soliris (eculizumab) is safe and effective for treating children with various types of hemolytic uremic syndrome (HUS), including atypical HUS (aHUS), according to a real-world study involving pediatric patients in Israel. In fact, more than half of the children with aHUS given Soliris in the study achieved a complete response, meaning they showed sustained normalization of blood parameters and kidney function improvements.
Plasma exchange therapy managed aHUS in elderly man: Report

2 months ago | ahusnews.com | Andrea Lobo

Plasma exchange therapy successfully managed atypical hemolytic uremic syndrome (aHUS) triggered by pancreas inflammation in a 72-year-old man, according to a case report from China. However, discontinuation of plasma exchange and a transition to hemodialysis - a treatment used to remove waste and excessive fluid from the blood when the kidneys are not functioning normally - led the patient to develop chronic kidney failure, per the report.
Plasma exchange therapy, Soliris manage aHUS in boy: Report

2 months ago | ahusnews.com | Marisa Wexler

Plasma exchange therapy followed by treatment with Soliris (eculizumab) was effective at managing atypical hemolytic uremic syndrome (aHUS) in a boy in China. The case was described in the report, " Plasma exchange combined with eculizumab in the management of atypical hemolytic uremic in pediatric patients: A case report ," which was published in Medicine.
Epysqli, Soliris biosimilar, now available for aHUS patients in US

2 months ago | ahusnews.com | Marisa Wexler

Epysqli (eculizumab-aagh), a biosimilar of Soliris (eculizumab), is now available for patients in the U.S., according to an announcement from Samsung Bioepis and Teva Pharmaceuticals. The biosimilar is authorized to treat people with atypical hemolytic uremic syndrome (aHUS), as well as paroxysmal nocturnal hemoglobinuria, and generalized myasthenia gravis - all of which are conditions that Soliris is approved to treat.
Woman with lupus developed aHUS after pregnancy in rare case

2 months ago | ahusnews.com | Marisa Wexler

A woman with lupus in her early 30s, who developed atypical hemolytic uremic syndrome (aHUS) after pregnancy, was not suspected of having the rare condition until five days after her baby's birth, which resulted in her not receiving the correct treatment, according to a case report from researchers in Japan. "In this case, delayed recognition of aHUS precluded the use of [appropriate] therapies," the researchers wrote.